Dermatology News and Research

Latest Dermatology News and Research

Positive results from Creabilis CT327 Phase IIa study in patients with psoriasis vulgaris

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results from its Phase IIa study of its lead product CT327 in psoriasis vulgaris.

10 Mar 2011

LRI announces 12 new research grants to drive innovation in lupus

The Lupus Research Institute today announced the award of 12 new research grants, building on its decade-long commitment to drive innovation and discover novel approaches to understand and treat one of the world's most confounding and elusive diseases - lupus.

9 Mar 2011

Fumaric acid salts may protect against Multiple Sclerosis

Fumaric acid salts have been in use against severe psoriasis for a long time. About ten years ago, researchers in Bochum speculated that they may also have a favourable effect on Multiple Sclerosis as a result of their TH2 polarizing mechanisms.

8 Mar 2011

Galderma, Astrazeneca collaborate to develop new compounds for dermatological disorders

AstraZeneca and Galderma Pharma S.A., a global speciality pharmaceutical company focused on dermatology, today announced they have entered into a R&D collaboration to develop new treatments for dermatological conditions including psoriasis, acne and atopic dermatitis which significantly affect the health and quality of life for millions of people worldwide.

7 Mar 2011

Scientist discovers new mechanism for regulation of gene expression

Dr. David Levin, Professor of Molecular & Cell Biology at Boston University Henry M. Goldman School of Dental Medicine and Professor of Microbiology at Boston University School of Medicine discovered recently a novel, evolutionarily conserved mechanism for the regulation of gene expression.

4 Mar 2011

Novabay commences NVC-422 catheter Phase 2 trial to treat UCBE

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, today provided an update on its Phase 2 clinical trial for the use of its lead compound, NVC-422, to prevent urinary catheter blockage and encrustation which is often a contributing factor to urinary tract infections in chronically catheterized patients.

2 Mar 2011

Research: Tanning bed exposure can lead to serious skin problems

Tanning bed exposure can produce more than some tanners may bargain for, especially when they self-diagnose and use the radiation to treat skin eruptions, according to research conducted by the Indiana University School of Medicine Department of Dermatology.

2 Mar 2011

EPO to grant patent for Apricus MycoVa product to treat nail fungus

Apricus Biosciences, Inc. announced today that the European Patent Office will grant a patent for the company's MycoVa product for treating onychomycosis.

2 Mar 2011

LEO selects Veeva CRM to support its rapidly growing New Markets Europe region

LEO Pharma, a leading global pharmaceutical company specialising in dermatology and critical care, has selected Veeva CRM to support its rapidly growing New Markets Europe region. LEO has started the deployment of Veeva CRM to its users in countries such as Hungary, Czech Republic, Slovakia, Poland, Romania, and Italy.

1 Mar 2011

Meda launches Medivir's cold sore treatment Xerese in the U.S.

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces that the Company's commercialization partner, Meda AB, has launched Medivir's unique cold sore treatment Xerese in the United States.

1 Mar 2011

New personalized therapy fools cancer cells into killing themselves

A Wayne State University School of Medicine physician-researcher has developed a personalized therapy to treat a wide range of cancers. The treatment is based on a naturally occurring human enzyme that has been genetically modified to fool cancer cells into killing themselves.

1 Mar 2011

Warner Chilcott fourth quarter revenue increases 1% to $694.4 million

Warner Chilcott plc today announced its results for the quarter and year ended December 31, 2010. As discussed more fully below, our financial position and results of operations in the quarter ended December 31, 2010 as compared to the prior year quarter were significantly impacted by several important transactions in 2009 and 2010.

25 Feb 2011

Scientists find bovine colostrum can massively reduce leaky gut syndrome

Scientists investigating natural ways to enhance athletic performance have found that bovine colostrum can massively reduce gut permeability - otherwise known as 'leaky gut syndrome.'

24 Feb 2011

Educational intervention may increase awareness about kidney transplant recipients' risk of developing skin cancer

Sharing printed educational materials about the risk of squamous cell carcinoma with kidney transplant recipients appeared to be effective at increasing skin self-examination and encouraging follow-up with a dermatologist to determine risk of cancer, according to a report posted online today that will appear in the June issue of Archives of Dermatology, one of the JAMA/Archives journals.

22 Feb 2011

Women with melanoma seem to experience more health-related quality of life issues than men

Women seem to experience more health-related quality of life issues than men for up to 10 years following a diagnosis of the skin cancer melanoma, according to a report in the February issue of Archives of Dermatology, one of the JAMA/Archives journals.

22 Feb 2011

Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia

ADVANCELL, an emerging biopharmaceutical company, today announced positive results from a clinical study conducted with Acadra (Acadesine) in Chronic Lymphocytic Leukemia patients resistant to current therapies. The company also announced promising non-clinical results in Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and other lymphoproliferative disorders. Synergism of Acadra in combination with current treatment in these indications has been demonstrated.

21 Feb 2011

Steering more women toward careers in surgery: WIS Career Symposium

The 2nd Annual National Women In Surgery Career Symposium will be held March 4 to 6 at the Hyatt Regency Clearwater Beach, featuring two of the few women chairs of academic surgery programs in the country as speakers.

19 Feb 2011

Fast Company ranks NovaBay 7th in biotech industry in 2011 annual list of world's most innovative companies

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has been ranked seventh in the biotech industry in Fast Company's annual list of the world's most innovative companies in 2011.

19 Feb 2011

Upsher-Smith expands voluntary recall of Jantoven Warfarin Sodium, 3 mg Tablets

Upsher-Smith Laboratories, Inc., of Maple Grove, Minnesota is voluntarily expanding its previously announced recall of Jantoven® Warfarin Sodium, USP, 3 mg Tablets to include additional products that were packaged on the same packaging line between May 17, 2010 and November 17, 2010.

19 Feb 2011

European Commission bans fragrance material Musk xylene, in line with global IFRA Standards

The European Commission has just announced its decision to ban the fragrance material Musk xylene under the new European Chemicals Legislation REACH, bringing EU regulations in line with the global IFRA Standards.

19 Feb 2011